Protocols

Canada hands Sanofi, Regeneron their first OK for sarilumab; Rigel raises $40 million

Mark W. Schwartz

• The FDA stiff-armed Sanofi and Regeneron’s rheumatoid arthritis drug sarilumab, but Canadian officials were happy to give the drug its first regulatory green light. The FDA’s CRL was pointed to some manufacturing problems at Sanofi, which it’s been working to overcome.  But most analysts expect a near-term US approval.

• Cerulean $CERU went 0 for 2 in Phase II last year, forcing a restructuring that eliminated half of its jobs. Now the company — which had $38 million in cash at the end of September — is following up with a look at its strategic alternatives.

• South San Francisco-based Rigel Pharmaceuticals has rounded up $40 million from a follow-on offering.

• Under investigation for its marketing practices, the biotech microcap Galena Biopharma $GALE has booted CEO Mark Schwartz.


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 13,500+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy





Bracket